Using immunological techniques urinary hCG, pregnancy-specific beta 1-glycoprotein (SP1) and beta-subunit of hCG (beta-hCG) levels were measured in the serum and cerebrospinal fluid of patients with trophoblastic tumours. After removal of hydatidiform moles, urinary hCG, beta-hCG and SP1 levels were similar, but SP1 levels tended to exceed serum beta-hCG levels. SP1 usually disappeared first. In patients with metastatic choriocarcinoma, SP1 levels appeared to be lower than beta-hCG values in serum and cerebrospinal fluid, but urinary hCG, beta-hCG and SP1 concentrations all decreased during chemotherapy. Measurements of SP1 levels may well be useful in the monitoring of patients being treated for trophoblastic tumours.

No abstract

No abstract

Danazol, a derivative of 17a-ethinyl testosterone which is a synthetic steroid with antigonadotropic properties has been used in the treatment of endometriosis. The efficacy of Danazol due to long-term administration resulted in a reduction of menstrual blood loss. The purpose of this investigation was to study not only the influence of Danazol on clotting and fibrinolytic activities for patients with endometriosis, but also to know that Danazol therapy may decrease menstrual blood loss in patients with hereditary hemorrhagic disease as reported by Soma et al.3)Results: 1) There were steady rises in F VIII and F IX after 4 months administration of Danazol, while no rises of such factors were observed in women given androgen. 2) No significant increase of platelets and other clotting factors was observed during Danazol treatment, even though a transient decrease of fibrinogen was seen. 3) No significant changes of fibrinolytic activities such as al-AT, a2-MG, AT-III and C1-INA were observed. 4) Plasma levels of kallikrein inhibitor at the onset of menstruation in women treated with Danazol was higher than the control group. 5) However, in vitro changes of clotting as

In an attempt to clarify the mechanism of blood flowing in the placental intervillous circulation, we investigated the possibility as to whether the placenta might have an inhibitory effect of platelet aggregation.Materials and Methods : Fresh, full-term placental extracts were prepared by washing several times in 0.01 M Tris at 4°C to remove contaminating blood and tissue fluids. Following centrifugation at 3, 000 r. p. m. for 15 minutes, the supernatant fluid was taken and centrifuged again. PRP was prepared by standard techniques. The extract was added to PRP and incubated at 37°C for 3 minutes. The effects of placental extracts on platelet aggregation were measured by using Lumi-aggregometer with inducers such as ADP, collagen, epinephrine and ristocetin.In addition, the inhibitory effects of placental lipids, placental proteins and PGI2 on platelet aggregation were investigated by the same method.Results : 1) The placental extracts inhibited not only the secondary platelt aggregation induced by ADP, but also the release reaction of ATP induced by collagen, epinephrine and ristocetin.2) The tissue extracts obtained from maternal side and central portion of the placenta also exhibited the strong inhibitory effect of platelt aggregation, but the umbilical cord vessels had little inhibitory effect on secondary aggregation.3) Tissue extracts of hydatidif orm mole showed not only a strong inhibitory effect of secondary aggregation, but also inhibited release reaction by ATP. 4) The inhibitory effect by placental